MXPA04010816A - Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares. - Google Patents

Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.

Info

Publication number
MXPA04010816A
MXPA04010816A MXPA04010816A MXPA04010816A MXPA04010816A MX PA04010816 A MXPA04010816 A MX PA04010816A MX PA04010816 A MXPA04010816 A MX PA04010816A MX PA04010816 A MXPA04010816 A MX PA04010816A MX PA04010816 A MXPA04010816 A MX PA04010816A
Authority
MX
Mexico
Prior art keywords
new uses
aminoalkanephosphonic acids
substituted
substituted aminoalkanephosphonic
acids
Prior art date
Application number
MXPA04010816A
Other languages
English (en)
Inventor
Ch Neijt Hans
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0209886A external-priority patent/GB0209886D0/en
Priority claimed from GB0209887A external-priority patent/GB0209887D0/en
Priority claimed from GB0209889A external-priority patent/GB0209889D0/en
Priority claimed from GB0210371A external-priority patent/GB0210371D0/en
Priority claimed from GB0212760A external-priority patent/GB0212760D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MXPA04010816A publication Critical patent/MXPA04010816A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere al uso de acidos aminoalcanfosfonicos substituidos en el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
MXPA04010816A 2002-04-30 2003-04-29 Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares. MXPA04010816A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0209886A GB0209886D0 (en) 2002-04-30 2002-04-30 Organic compounds
GB0209887A GB0209887D0 (en) 2002-04-30 2002-04-30 Organic compounds
GB0209889A GB0209889D0 (en) 2002-04-30 2002-04-30 Organic compounds
GB0210371A GB0210371D0 (en) 2002-05-07 2002-05-07 Organic compounds
GB0212760A GB0212760D0 (en) 2002-05-31 2002-05-31 Organic compounds
PCT/EP2003/004466 WO2003092701A2 (en) 2002-04-30 2003-04-29 Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders

Publications (1)

Publication Number Publication Date
MXPA04010816A true MXPA04010816A (es) 2005-03-07

Family

ID=29408096

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04010816A MXPA04010816A (es) 2002-04-30 2003-04-29 Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.

Country Status (13)

Country Link
US (1) US20060293282A1 (es)
EP (1) EP1501518A2 (es)
JP (2) JP2005527600A (es)
KR (1) KR20040101573A (es)
CN (1) CN1649599A (es)
BR (1) BR0309611A (es)
CA (1) CA2482524A1 (es)
IL (1) IL164779A0 (es)
MX (1) MXPA04010816A (es)
NO (1) NO20045089L (es)
PL (1) PL371427A1 (es)
TW (1) TW200403066A (es)
WO (1) WO2003092701A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0310868D0 (en) * 2003-05-12 2003-06-18 Novartis Ag Organic compounds
GB0324541D0 (en) * 2003-10-21 2003-11-26 Novartis Ag Organic compounds
GB0324542D0 (en) * 2003-10-21 2003-11-26 Novartis Ag Organic compounds
GB0325175D0 (en) * 2003-10-28 2003-12-03 Novartis Ag Organic compounds
GB0325172D0 (en) * 2003-10-28 2003-12-03 Novartis Ag Organic compounds
GB0325390D0 (en) * 2003-10-30 2003-12-03 Novartis Ag Organic compounds
GB0405034D0 (en) * 2004-03-05 2004-04-07 Novartis Ag Organic compounds
ITMI20071492A1 (it) 2007-07-24 2009-01-25 S I I T Srl Servizio Internazi "composizioni per il trattamento e la prevenzione di condizioni di vertigine e acufeni comprendenti citicolina, estratto di ginkgo biloba e flavoni dimerici di ginkgo biloba"

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994467A (en) * 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
GB9400680D0 (en) * 1994-01-14 1994-03-09 Sandoz Ltd Improvements in or relating to organic compounds
DE4439492A1 (de) * 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
AU4423496A (en) * 1995-03-14 1996-10-02 Warner-Lambert Company Novel glutamate (ampa/kainate) receptor antagonists: n-substituted fused azacycloalkylquinoxalinediones
MY132385A (en) * 1995-08-31 2007-10-31 Novartis Ag 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives
GB9604400D0 (en) * 1996-03-01 1996-05-01 Pfizer Ltd Compounds useful in therapy
WO1997046539A1 (en) * 1996-06-05 1997-12-11 Warner-Lambert Company Amide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
SK282548B6 (sk) * 1996-10-24 2002-10-08 Novartis Ag Substituované aminoalkánfosfónové kyseliny, spôsob ich prípravy, farmaceutické prostriedky, ktoré ich obsahujú, a ich použitie
SE508138C2 (sv) * 1996-12-20 1998-08-31 Ericsson Telefon Ab L M Metod och anordning för anslutning av elektrisk komponent till kretskort
GB9802225D0 (en) * 1998-02-02 1998-04-01 Cerebrus Ltd Chemical compounds
US6291479B1 (en) * 1998-12-03 2001-09-18 Alcon Manufacturing, Ltd. Use of NR2B-selective NMDA-receptor antagonists for the treatment of ophthalmic diseases
GB0018272D0 (en) * 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
DE10048969A1 (de) * 2000-08-23 2002-03-14 Mueller Schwefe Gerhard Verwendung von Flupirtin zur Tinnitusbehandlung
JP2004515477A (ja) * 2000-12-07 2004-05-27 ニューロモレキュラー インコーポレイテッド Ｎｍｄａレセプターアンタゴニストを用いて神経精神医学的障害を処置するための方法

Also Published As

Publication number Publication date
JP2009137995A (ja) 2009-06-25
TW200403066A (en) 2004-03-01
WO2003092701A2 (en) 2003-11-13
IL164779A0 (en) 2005-12-18
PL371427A1 (en) 2005-06-13
EP1501518A2 (en) 2005-02-02
US20060293282A1 (en) 2006-12-28
WO2003092701A3 (en) 2004-04-08
BR0309611A (pt) 2005-02-09
CN1649599A (zh) 2005-08-03
AU2003232224A1 (en) 2003-11-17
CA2482524A1 (en) 2003-11-13
KR20040101573A (ko) 2004-12-02
NO20045089L (no) 2004-11-23
JP2005527600A (ja) 2005-09-15

Similar Documents

Publication Publication Date Title
HRP20020593B1 (en) Brain, spinal and nerve injury treatment
MA27929A1 (fr) Utilisation de calcitonine pour le traitement de l'osteoarthrite
WO2004019884A3 (en) Agents and methods for enhancing bone formation
DE60020613D1 (de) (S,S)-Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
MXPA03001960A (es) Un metodo para tratar alergias.
DE60101265D1 (de) Behandlung von augenschmerzen
CY1106155T1 (el) Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους
WO2003100574A3 (en) Dental appliances and systems and methods for distributing dental appliances
DE602004023762D1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
MY135829A (en) Analeptic and drug combinations
DK1463735T3 (da) Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider
EE05357B1 (et) Tablett, mis sisaldab v„hemalt kahte eristatavat segmenti, ning selle kasutamine
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
BR9914848A (pt) Composição e processo para o tratamento de distúrbios da retina externa
ATE448779T1 (de) Methode zur behandlung trockener augen und uveitis
MXPA03010406A (es) Tratamiento novedoso para el desorden obsesivo-compulsivo (ocd) y desordenes relacionados con ocd.
TR200200278T2 (tr) Kalsilitik bileşimler
DK1463563T3 (da) Superoxiddismutas-mimetika til behandling af öjenlidelser og -sygdomme
DE60228988D1 (de) Monohyroxycarbamezepin zur verwendung bei der herstellung eines medikaments zur behandlung von affektiver psychose, aufmerksamkeits störungen und neuropathischen schmerzen
WO2005021026A3 (en) Methods for treating or ameliorating ghrelin-associated diseases and disorders
GB2411356B (en) Compositions useful in treating affective, painful or allergic disorders
MXPA05012696A (es) Formulaciones de agentes antiinflamatorios no esteroides para tratar angiogenesis ocular patologica.
TW200508196A (en) Hydroxamic acids useful in the treatment of hyper-proliferative disorders
ATE286390T1 (de) Felabamat-derivate zur behandlung von neuropathischem schmerz
AU2001282832A1 (en) New use of quetiapine